Continuing to deny Medicare coverage for beta amyloid positron emission tomography scans that could help clarify causes of dementia is jeopardizing patient access to care and “threatens to stifle further innovation,” a patient advocacy group says.
CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.
More from Policy & Regulation
More from Medtech Insight
• By
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.
• By
The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.